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Obesity has been linked with an increased risk of prostate cancer. The formation of toxic free oxygen radicals has been implicated
in obesity mediated disease processes. Leptin is one of the major cytokines produced by adipocytes and controls body weight
homeostasis through food intake and energy expenditure. The rationale of the study was to determine the impact of leptin
on the metastatic potential of androgen-sensitive (LNCaP) cells as well as androgen-insensitive (PC-3 and DU-145) cells. At a
concentration of 200 nm, LNCaP cells showed a signiﬁcant increase (20% above control; P<. 0001) in cellular proliferation
without any eﬀect on androgen-insensitive cells. Furthermore, exposure to leptin caused a signiﬁcant (P<. 01 to P<. 0001) dose-
dependent decrease in migration and invasion of PC3 and Du-145 prostate carcinoma cell lines. At the molecular level, exposure
of androgen-independent prostate cancer cells to leptin stimulates the phosphorylation of MAPK at early time point as well as
the transcription factor STAT3, suggesting the activation of the intracellular signaling cascade upon leptin binding to its cognate
receptor. Taken together, these results suggest that leptin mediates the invasive potential of prostate carcinoma cells, and that this
eﬀect is dependent on their androgen sensitivity.
Copyright © 2008 Dayanand D. Deo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Prostate cancer is the second leading cause of cancer related
death among American men [1]. Obesity has assumed
epidemic proportions in the United States and has been
linked with increased risk of prostate, breast, colon, and
endometrial cancers [2–7]. More recently, there have been
several studies suggesting that obesity may impact upon risk,
detection, and outcome with regard to prostate cancer [8].
Leptin, one of the major adipose cytokines controls body
weight by regulating food intake and energy expenditure
[9, 10]. Adipose tissue leptin mRNA and circulating leptin
levels increase in obesity. Clinical studies have demonstrated
that, blood leptin levels are associated with clinically rele-
vant prostate cancer [11, 12], although some studies have
questioned these results [13–16]. In vitro, leptin has been
postulated as a growth promoter for androgen-independent
DU-145 and PC-3 cells [17–20], but not in androgen-
dependent LNCaP cells [20]. Several reports have demon-
strated that leptin induces the formation of toxic oxygen
radicals [21–25]. Oxidant damage has been implicated as a
major causative factor in obesity mediated disease processes.
The rationale of the present study is to conﬁrm the role
of leptin on the metastatic potential of prostate carcinoma2 Journal of Biomedicine and Biotechnology
cells. We tested androgen-sensitive LNCaP cells as well
as androgen-resistant PC-3 and DU-145 cells for their
ability to metastasize in the presence and absence of leptin.
Additionally, we investigated the eﬀect of leptin on mitogen-
activated protein kinase (MAPK) phosphorylation, and on
the activation of Erk-1 and Erk-2, and STAT-3.
2. MATERIALS AND METHODS
2.1. Reagents
Leptin was obtained from Sigma-Aldrich Inc., St. Louis, Mo.
Antibodies used were rabbit polyclonal antiphospho-p44/42
MAP kinase, rabbit polyclonal anti-STAT-3, rabbit poly-
clonal antiphospho-STAT-3, and horseradish peroxidase-
conjugated goat antirabbit antibodies from Cell Signaling
Technology, Beverly, Mass.
2.2. Cellculture
The PC-3 and LNCaP cell lines were propagated in RPMI
1640 medium, whereas DU-145 cell line was propagated in
EMEM medium (Invitrogen Corporation, Carlsbad, Calif)
supplemented with 10% FBS (HyClone, Logan, Utah). For
protein studies, cells were grown to subconﬂuent levels in
RPMI or EMEM, respectively, and supplemented with 10%
FBS in 6-well culture plates (106 cells/well). The cells were
then washed once with basal medium and starved of growth
factors by switching them to basal medium containing
1% FBS for 16 hours. Cells were again washed once with
basal medium and then exposed to various experimental
conditions for diﬀerent time points. At the end of each time
point, cells were washed with ice-cold phosphate-buﬀered
saline (PBS, Invitrogen), lysed in cell lysis buﬀer containing
50mM Tris-HCl (pH 7.5), 1mM EDTA, 1mM EGTA, 2mM
Na3VO4, 50mM NaF, 70mM 2-mercaptoethanol, 1%v/v
Triton X-100, 2%w/v SDS, and 1μg/ml protease inhibitor
mixture (Sigma-Aldrich, Mo). Cell lysates were used as
indicated below.
2.3. Proliferationassay
RPMI or EMEM + 10% FBS was added to each well of
a 24-well plate and pretreated for 4 hours with various
concentrations of leptin at 37
◦Ci naC O 2 incubator. Growth
factor starved PC-3, LNCaP, or DU-145 cells were then
t r a n s f e r r e dt oe a c hw e l l( 2× 104 cells/well) along with
1μM[ 3H]Thymidine, and incubated in the CO2 incubator.
After 144 hours of incubation, the cells were then washed
three times with ice-cold saline, precipitated with 10% TCA,
washed with methanol and air-dried. The labeled DNA
was dissolved in 0.05N NaOH at 37
◦C, neutralized with
0.05N HCl, transferred to scintillation vial containing the
scintillation cocktail and counted.
2.4. Invitromigrationandinvasionassay
A modiﬁed Boyden chamber method using Transwell mem-
braneinserts(Costar,Corning,NY)wasusedtomeasurePC-
3 and DU-145 migration and invasion. For invasion studies,
Matrigel (BD Biosciences, Bedford, Mass) was added to the
upper surface of the Transwell membrane and allowed to
solidify in a sterile environment for 24 hours. PC-3 or DU-
145 cells (14×104 cells/ml) were suspended in basal medium
supplemented with 2% FBS, and 0.02% BSA, incubated with
various concentrations of leptin, and plated onto the upper
surface of the Transwell membrane inserts in a total volume
of 100μL. Basal medium supplemented with 2% FBS and
0.02%BSAwasaddedtothelowerchamberinatotalvolume
of 400μL. The cells were then incubated at 37
◦Ci naC O 2
incubator. After 10 hours of incubation, cells present on the
upper surface of the membrane were scraped oﬀ, and the
cells that had migrated to the lower surface of the membrane
were ﬁxed, stained and counted using an inverted Axiovert
25 microscope (Carl Zeiss, Thornwood, NY).
2.5. Westernblotting
Prostate cancer cells, pretreated for 16 hours with basal
medium supplemented with 1% FBS, were treated with 25,
50, 100, and 200ng of leptin for various time points. After
the completion of each time point, the cells were lysed
in the cell lysis buﬀer containing 0.1%w/v bromophenol
blue. The samples were boiled for 5 minutes and separated
using 7.5% SDS-PAGE (40μg of total protein/lane). The
separated proteins were then transferred onto nitrocellulose
membranes (Bio-Rad, Hercules, Calif), blocked with Tris-
buﬀered saline containing 5% nonfat dry milk for 1 hour at
room temperature, and incubated with the respective anti-
bodies against the proteins in Tris-buﬀered saline containing
5% nonfat dry milk and 0.5% Tween 20, overnight at 4◦C.
After washing and incubation with horseradish peroxidase-
conjugated secondary antibody, the proteins were revealed
using the enhanced chemiluminescent detection kit (Pierce
Biotechnology, Biotechnology, Rockford, Ill).
2.6. Statisticalanalysis
The data were analyzed using the Statview software to obtain
the SE values and the signiﬁcance (P) values for the various
results from 3 separate experiments.
3. RESULTS
3.1. Leptinattenuatescellularinvasionof
androgen-resistantprostatecancercells
Androgen-resistant PC-3 cells and DU-145 cells were sus-
pendedinmediaalongwithincreasingconcentrationsoflep-
tin and plated onto the upper surface of the Transwell inserts
that were previously coated with Matrigel, as described
in Material and Methods section. As seen in Figure 1(a),
leptin attenuated the invasion of Matrigel by PC-3 cells as
well as DU-145 cells in a concentration dependent manner,
with signiﬁcant attenuation observed at 50ng, 100ng, and
200ng concentrations of leptin, indicating that nanogram
concentrations of leptin inhibit the invasive capacity of these
androgen-independent prostate carcinoma cell lines.Dayanand D. Deo et al. 3
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Figure 1: Cellular invasion and migration of androgen-resistant prostate cancer cells are attenuated by leptin. PC-3 and DU-145 cells were
suspended in basal medium supplemented with 2% FBS, and 0.02% BSA, incubated with various concentrations of leptin, and plated
onto the upper surface of the Transwell membrane inserts. For invasion studies, Matrigel was added to the upper surface of the Transwell
membrane and allowed to solidify in a sterile environment for 24 hours. After 10 hours of incubation at 37
◦Ci naC O 2 incubator, cellular
invasion(a)andmigration(b)weremeasuredbycountingthecellsthathadmigratedtothelowersurfaceofthemembrane.Valuesrepresent
the mean ± S.E. of triplicate samples of a representative experiment.
3.2. MigrationofPC-3cellsandDu-145cells
isattenuatedbyleptin
Androgen-independent PC-3 cells and DU-145 cells were
incubated with increasing concentrations of leptin (see
Figure 1(b)) and allowed to migrate through the pores of
the membrane in the modiﬁed Boyden chamber containing
transwell inserts. Attenuation of migration of both PC-3 and
Du-145 cell lines was observed in the presence of increasing
concentrations of leptin, with signiﬁcant attenuation being
observed at 100ng and 200ng concentrations of leptin for
PC-3 cells and at 200ng concentration of leptin for DU-145
cells, respectively, suggesting that leptin at nanogram con-
centrations inhibits the mechanism regulating the migration
of these cell lines.
3.3. Leptininducestheproliferationof
androgen-dependentprostatecancercells
Proliferation of androgen-dependent and independent
prostate cancer cell lines was observed in the presence
of nanogram concentrations of leptin. After achieving the
basal level of growth by overnight incubation in basal
medium, increasing concentration of leptin was added to
the cells, respectively. As seen in Figure 2, a dose-dependent
increase in proliferation was observed when the androgen-
dependent LNCaP cells were incubated with leptin, with
signiﬁcant growth being observed at 50ng, 100ng, and
200ng concentrations of leptin, respectively. There was no
change in growth of androgen-independent PC-3 cells and
Du-145 cells in the presence of increasing concentration
of leptin (data not shown), suggesting that leptin induces
the proliferative capacity of only the androgen-dependent
prostate carcinoma cell lines.
3.4. LeptinstimulatedMAPKphosphorylation
We hypothesized that binding of leptin to its receptors in
the prostate cancer cell lines would lead to the early phos-
phorylation of MAPK. To test this hypothesis, androgen-
dependent LNCaP cells and androgen-independent PC-3
and DU-145 cells were starved of growth factors overnight
(basal medium supplemented with 1% FBS), following
which they were exposed to increasing concentration of
leptin for various time points. Phosphorylation of MAPK4 Journal of Biomedicine and Biotechnology
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Figure 2: Proliferation of androgen-dependent prostate cancer cells is
inducedbyleptin.GrowthfactorstarvedLNCaPcellswereincubated
with increasing concentrations of leptin, and proliferation was
measured by the incorporation of [3H]thymidine after 144 hours.
Values represent the mean ± S.E. of triplicate samples of a
representative experiment.
was observed at the end of each time point for all cell lines.
Interestingly, leptin did not induce the phosphorylation of
MAPK in the androgen-dependent LNCaP cells (data not
shown). However, in androgen-independent prostate cancer
cell lines, phosphorylation of MAPK was observed to be
maximal at 15 minutes (PC-3 cells, see Figures 3(a) and
3(b)) and 10 minutes (DU-145 cells, see Figures 3(c) and
3(d)) upon exposure to leptin. Maximal increase in MAPK
phosphorylation was observed upon incubating these cells
with 100ng and 200ng of leptin, respectively, suggesting that
binding of leptin to its receptors induces an intracellular
signaling cascade leading to the phosphorylation of MAPK
in the androgen-independent prostate cancer cell lines.
3.5. STAT-3phosphorylationisinducedbyleptin
Afteranovernightincubationinbasalmediumwith1%FBS,
androgen-dependent (LNCaP) and -independent (PC-3)
prostate cancer cells were incubated with a dose-dependent
increase in leptin levels for various time points. STAT-3
phosphorylation was investigated over time for both cell
lines. As seen in Figures 4(a) and 4(b), leptin induced
the time-dependent phosphorylation of STAT-3 in PC-3
cells, reaching maximal levels after 15 minutes of exposure,
and returning to baseline after 60 minutes of incubation.
Exposure of PC-3 cells to increased leptin levels led to
a correspondent increase in the level of maximal STAT-
3 phosphorylation at the 15 minutes time point. Leptin
exposure also induced the phosphorylation of STAT-3 in
LNCaP cells (see Figures 4(c) and 4(d)), reaching maximal
levels after 30 minutes of stimulation. However, in LNCaP
cells, STAT-3 remained phosphorylated even after prolonged
(60 minutes) exposure to leptin, suggesting that leptin
induces the phosphorylation of STAT-3 only at an early time
point in androgen-independent cells, while in androgen-
dependent prostate cancer cells, STAT-3 phosphorylation is
a delayed but prolonged event.
4. DISCUSSION
It has been shown that leptin inﬂuences the proliferation and
migration of endothelial and epithelial cells and is capable
of promoting angiogenesis [21]. In vitro studies on prostate
cancer cell lines showed that leptin promotes proliferation
of androgen-independent prostate cancer [20]. Leptin also
induces cell migration and the expression of growth factors
in prostate cancer cells, suggesting that studies undertaken
to ascertain leptin and/or obesity association to prostate
cancer should diﬀerentiate patients according to androgen
resistance [19]. Leptin has been demonstrated to potently
induce the invasion of endometrial cancer cells [22]a n d
also contributes to the invasive phenotype of colonic and
kidney epithelial cells at various stages of the neoplastic
progression [23]. Our results demonstrate that the invasive
and migratory capabilities of androgen-insensitive prostate
cancer cells are attenuated upon exposure to nanogram
concentrationsofleptinforashortdurationof10hours,and
that this attenuation increases in a dose-dependent manner.
Our observations are in contrast to those of Frankenberry et
al. [19] who demonstrated that a longer 24 hour exposure
of leptin increased the migration of androgen-independent
prostate cancer cells. We did not observe any change in
the proliferation of androgen-independent prostate cancer
cells upon exposed to nanogram concentrations of leptin
(data not shown). In contrast, the proliferation of androgen-
sensitive prostate cancer cells is increased in a dose-
dependent manner when they are exposed to nanogram
concentrations of leptin, suggesting leptin’s ability to dif-
ferentiate between the androgen-sensitive and -insensitive
prostate carcinoma cells. Our results are in contrast to those
observed by Onuma et al. [20] who showed an increased
proliferation of androgen-independent prostate cancer cells
using high (microgram) levels of leptin. Our contrasting
observations using very low (nanogram) levels of leptin
suggestthatprostatecancercellsareverysensitiveandbehave
diﬀerently at varying levels of leptin exposure.
As prostate cancer progresses, decreased androgen levels
promote the growth of androgen-resistant prostate cells.
T h e s ec e l l sa r eh y p e r s e n s i t i v et og r o w t hf a c t o r sa n dc e l l
regulators, especially mitogenic factors. The source of these
growth factors and cytokines, in addition to outside factors
aﬀecting their expression, is important to understanding
the progression of prostate cancer disease [21]. The leptin
signal is transduced through the leptin receptor (LEPR).
The diﬀerent isoforms of this receptor arise from alternate
splicing of the precursor mRNA [24]. The “long form”
LEPRb leptin receptor is the only isoform that forms
an IL-6-type homodimer and associates with the Janus
kinase 2 (JAK2) tyrosine kinase to mediate intracellular
signaling.JAK2phosphorylatesitselfandthetyrosineresidue
(Tyr 985) on the intracellular tail of the LEPRb receptor.
This phosphorylated tyrosine residue on the receptor then
recruits the adaptor protein Grb-2 and p21ras, ultimately
leadingtothephosphorylationandactivationofMAPK[25].
Our observations demonstrate that exposure of androgen-
independent prostate cancer cells to leptin does indeed
stimulate the phosphorylation of MAPK at an early timeDayanand D. Deo et al. 5
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Figure 3: Leptin stimulates MAPK phosphorylation in PC-3 and DU-145 cells. Growth factor-starved PC-3 (a) or DU-145 cells (c) were
exposed to increasing concentration of leptin for various time points. Cell lysates obtained after each time point were separated on a
7.5% SDS-PAGE and Western-blotted. Phosphorylated MAPK levels were obtained after incubation with p44/42 MAPK antibody and
chemiluminescent detection. (b) and (d), levels of p44/42 MAPK obtained after densitometric analysis and represented as percentage of
control against time (control being set at 100%). The results of one of the three independent experiments are shown.
point, suggesting the stimulation of the intracellular signal-
ingcascadeuponleptinbindingtoitscognatereceptoronthe
cell surface of these cells. Our observations are in accordance
with those reported earlier by Banks et al. [25] suggesting
involvement of MAPK activation upon binding of leptin to
its surface receptor. Interestingly, we did not observe MAPK
phosphorylation when the androgen-sensitive prostate can-
cer cells were exposed to leptin, suggesting the involvement
of a diﬀerent signaling cascade in these cells.
Activated JAK2 induces the phosphorylation of another
tyrosine residue (Tyr 1138) on the intracellular tail
of the LEPRb receptor, which binds and mediates the
phosphorylation-dependent activation of signal transducer
and activator of transcription 3 (STAT3). STAT proteins
r e g u l a t eg e n ee x p r e s s i o nb ya ﬀecting transcription. They are
part of the signal transduction pathway of many growth
factors and cytokines and are activated by phosphorylation
of tyrosine and serine residues by upstream kinases [26]. In
benign cells, the signaling by STAT3 is under tight regulation
so that the signal is transient. However, aberrant signaling by
STAT3 is observed in many types of malignancies, such as
myeloma, head and neck cancer, breast cancer, and prostate
cancer [27]. Malignant cells expressing persistently activated
STAT3 become dependent on it for survival; disruption
of activation or expression of STAT3 resulted in apoptosis
[28]. Lou, et al. have shown that STAT3 signaling is critical
for the growth and survival of prostate cancer cells [29].
We observed the involvement of STAT3 phosphorylation
in prostate cancer cells, which is concurrent with earlier
published reports, thus suggesting that this transcription
factor is an integral part in the leptin signal-transduction
cascade. Our observations further suggest that STAT3
phosphorylation can diﬀerentiate between the androgen
sensitivity of prostate cancer cells when they are exposed to6 Journal of Biomedicine and Biotechnology
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Figure 4: Leptin stimulates early phosphorylation of STAT-3 in PC-3 cells. PC-3cells (a) or LNCaP cells (c), devoid of growth factors by
an overnight exposure to basal medium, were exposed to increasing concentrations of leptin for various time points. 25μgo ft h ec e l l
lysates obtained after each time point were separated on a 7.5% SDS-PAGE and Western-blotted, and the phosphorylated STAT-3 proteins
were revealed by incubating with phospho-STAT-3 antibody followed by chemiluminescent detection. The membranes were stripped and
reprobed with STAT-3 antibodies to verify the protein levels. In (b) and (d), densitometric analysis of phospho-STAT-3 and STAT levels
was determined. A time-course, dose-response curves of phosphor-STAT-3/STAT-3 (PSTAT/STAT) ratios for the eﬀect of increasing leptin
concentrations are depicted for both (b) PC3 and (d) LNCaP. The original western blots are shown in (a) and (c). Results shown are
representative of three separate experiments.
nanogram levels of leptin. In androgen-independent PC-3
prostate cancercells,leptin induces an early phosphorylation
of STAT-3, which then decreases with time to the baseline
level, whereas in androgen-sensitive LNCaP cells, a delayed
and prolonged STAT3 phosphorylation is observed upon
exposure to leptin. It has been previously demonstrated that
part of leptin action is mediated through the generation of
toxic oxygen radicals [30]. Although, in this study we did
not measure a direct cause-eﬀect relationship between free
radical generation, and the changes in metastatic potential
of prostate cancer cells, indirect evidence of the role of free
radicals in this process is available in studies investigating the
use of antioxidants in prostate cancer [31].
In conclusion, binding of leptin to its surface receptor
induces a signal transduction cascade that has slight varia-
tions depending on the androgen sensitivity of the prostate
cancer cells. These variations in the intracellular signaling
eventsaretranslatedintobiologicalconsequencessuchasthe
invasive, migratory, and proliferative capabilities of prostate
carcinoma cells that are drastically diﬀerent between the
androgen-independent and -sensitive prostate cancer cells.
Thus, diﬀerentiation of the metastatic potential of prostateDayanand D. Deo et al. 7
cancer cells on the basis of their androgen sensitivity can
be observed when they are exposed to low levels of leptin.
Since a majority of leptin’s eﬀects (at least on metabolism)
are centrally mediated, the in vivo eﬀects of leptin on the
metastatic potential of prostate cancer cells may diﬀer from
the in vitro observations. However, mechanism-dependent
variations in the eﬀects of leptin treatment on the basis of
androgensensitivityofprostatecancercellscangiveusavital
insight into the possible in vivo eﬀects of leptin.
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